XML 32 R14.htm IDEA: XBRL DOCUMENT
v3.24.3

Expenses | 12 Months Ended
--- | ---
Jun. 30, 2024
Text block [abstract] |
Expenses | Note 9. Expenses
|  | 2024 A$’000 |  |  | 2023 A$’000 |  |  | 2022 restated A$’000 |
Research and development |  |  |  |  |  |  |  |  |  |  |  |
EVT-801 program costs |  |  | 5,277 |  |  |  | 5,060 |  |  |  | 2,520 |
Cantrixil program costs |  |  | 1 |  |  |  | 5 |  |  |  | 12 |
Paxalisib program costs |  |  | 7,551 |  |  |  | 5,618 |  |  |  | 13,713 |
Scientific Advisory Board costs |  |  | — |  |  |  | 31 |  |  |  | — |
Employee benefits expense - salaries & wages and staff benefits |  |  | 2,161 |  |  |  | 2,250 |  |  |  | 1,665 |
- superannuation |  |  | 36 |  |  |  | 29 |  |  |  | 25 |
- share based payments |  |  | 485 |  |  |  | 702 |  |  |  | 365 |
Total research & development (excluding amortisation) |  |  | 15,511 |  |  |  | 13,695 |  |  |  | 18,300 |
Amortisation |  |  |  |  |  |  |  |  |  |  |  |
Paxalisib licensing agreement |  |  | 1,084 |  |  |  | 1,084 |  |  |  | 1,084 |
Evotech licensing agreement |  |  | 785 |  |  |  | 785 |  |  |  | 785 |
Total amortisation |  |  | 1,869 |  |  |  | 1,869 |  |  |  | 1,869 |
Total research & development |  |  | 17,380 |  |  |  | 15,564 |  |  |  | 20,169 |
Net foreign exchange loss |  |  |  |  |  |  |  |  |  |  |  |
Net foreign exchange (gain) / loss |  |  | (20 | ) |  |  | 46 |  |  |  | (2,154 | )
Rental expense relating to operating leases |  |  |  |  |  |  |  |  |  |  |  |
Minimum lease payments |  |  | 124 |  |  |  | 152 |  |  |  | 73 |
Superannuation expense |  |  |  |  |  |  |  |  |  |  |  |
Defined contribution superannuation expense |  |  | 88 |  |  |  | 131 |  |  |  | 138 |
Employee benefits expense G&A |  |  |  |  |  |  |  |  |  |  |  |
- salaries & wages and staff benefits |  |  | 486 |  |  |  | 1,467 |  |  |  | 1,674 |
- superannuation |  |  | 52 |  |  |  | 102 |  |  |  | 129 |
- share based payments |  |  | 48 |  |  |  | 457 |  |  |  | 1,310 |
Total employee benefits expense G&A |  |  | 586 |  |  |  | 2,026 |  |  |  | 3,113 |

X
- Definition The disclosure of expenses. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 10 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisclosureOfExpensesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Text block [abstract] + References No definition available. + Details
Name: | kzia_TextBlockAbstract
Namespace Prefix: | kzia_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration